Document:

Side Letter Agreement

 Exhibit 10.29 
 September 5, 2007 
 QLT USA, INC. (“QLT USA”) 
 2579 Midpoint Drive 
 Fort Collins, CO 80525 
 Attention: Sean Moriarty 
 Dear Sirs: 
 Reference is made to the License and Development Agreement made as of September 5, 2007 by and between BioDelivery Sciences International, Inc. (“BDSI”), Arius Pharmaceutical, Inc.
(“Arius”) and Meda AB (“Meda”) (the “Meda License Agreement”), a copy of which is attached hereto as Exhibit A. Unless expressly provided otherwise herein, terms defined in the Meda License
Agreement shall have the same meanings herein. 
 1. The Licensed Technology for which Meda has been granted a sublicense under the Meda
License Agreement consists of Licensed Technology that is owned or controlled by CDC or by Arius Two, a wholly owned subsidiary of BDSI. The Licensed Technology in which CDC has an interest is subject to a license agreement dated July 14, 2005,
as amended, between CDC and Arius (the “CDC License”). The Licensed Technology owned by Arius Two is subject to a license agreement dated as of the date hereof between Arius Two and Arius, as amended (the “Arius Two
License”). QLT USA has a security interest in the Licensed Technology owned by Arius Two and in the Arius Two License under a Security Agreement dated as of the date hereof between QLT USA and Arius Two, as amended (the “Security
Agreement”). As a result of the foregoing arrangements the Meda License Agreement and the rights granted to Meda thereunder are subordinate to the CDC License, the Arius Two License and subject to the prior rights of QLT USA under the
Security Agreement. 
 2. QLT and Meda hereby agree as follows: 
 (a) If, and solely to the extent, in the exercise of its rights under Section 8 of the Security Agreement, QLT USA requests, in its sole discretion, but without any obligation to do so, Arius Two to assign all of
its right, title and interest in and to the Arius Two License to QLT USA, QLT USA and Meda agree that: 
 (i) such assignment
shall not result in the termination of Meda’s rights under the Arius Two License as set forth in Meda License Agreement, even if the rights of Arius and CDC are terminated under the Arius Two License (including, without limitation, rendering an
exclusive license non-exclusive) with respect to the Fentanyl Product (as defined in the Arius Two License); 
 (ii) Meda
shall continue the undisturbed enjoyment of its rights under, and subject to the terms and conditions of (including the right of termination in the event of a default by Meda), the Arius Two License; 

 (iii) Meda shall, following the assignment of Arius Two’s interests in the New
License Agreement (as defined in the Security Agreement) to QLT USA and a subsequent assignment of the Meda License Agreement to QLT USA as the direct licensor of Meda thereunder, make all future payments due under the Meda License Agreement to QLT
USA or its designee until further notified by QLT USA in writing; and 
 (iv) Meda shall be deemed a third-party beneficiary
of Section 8(f) of the Security Agreement and QLT USA agrees not to revise the terms of Section 8(f) of the Security Agreement in a manner adverse to Meda, without Meda’s prior written consent, which consent shall not be unreasonably
withheld. 
 (b) If QLT exercises its rights under Section 8 of the Security Agreement, any sale or transfer of the Collateral shall be
subject to the New License Agreement and any such sale or transfer shall not terminate the New License Agreement (as defined in the Security Agreement) or the Meda License Agreement. 
 3. Except as expressly provided herein, nothing contained in this letter agreement shall be construed as affecting the rights of Arius Two, CDC or QLT
USA in or with respect to the Licensed Technology. 
 4. This Letter Agreement will be governed by and interpreted in accordance with the
internal laws of the State of New York, without regard to its conflicts of laws rules. If and to the extent that any of the parties hereto are parties to agreements that are or may be at variance with the terms and conditions of this Letter
Agreement, the terms of this Letter Agreement shall control. 
 Please indicate your agreement to the provisions of this Letter Agreement by having a duly
authorized officer of each of the addressees execute this Letter Agreement in duplicate and then return an executed copy to the undersigned. 
  

									
	 	 	 	 	 	 	Very truly yours,
				
		 		 		 	MEDA AB
					
		 		 		 	By:	 	 /s/ Anders Lonner

		 		 		 	Name:	 	Anders Lonner
		 		 		 	Title:	 	Chief Executive Officer
				
	ACCEPTED AND AGREED TO AS OF	 		 		 	
	THE DATE OF THIS LETTER AGREEMENT:	 		 		 	
				
	QLT USA, INC.	 		 		 	
					
	By:	 	 /s/ Michael R. Duncan
	 		 		 	
	Name:	 	Michael R. Duncan	 		 		 	
	Title:	 	President	 		 		 	

 EXHIBIT A 
 MEDA LICENSE AGREEMENTConfirmation to Meda

 Exhibit 10.30 
 September 5, 2007 
 Meda AB 
 Box 906 

Pipers vag 2A 
 17009 
 Solna, Sweden 
 Attention: Anders Lonners, CEO 
 Dear Anders: 
 This letter will confirm our agreement with
Meda that neither BDSI, Arius nor Arius Two will take any action to amend, modify or terminate any agreement with a third party which would cause a termination or modification of Meda’s rights under the License and Development Agreement dated
as of the date hereof, and each document, instrument, agreement, license and/or sublicense related thereto, unless provision is made for Meda’s rights under such License and Development Agreement and such related documents to continue
undisturbed. 
  

			
	Very Truly Yours,
	
	BioDelivery Sciences International, Inc.
		
	By:	 	 /s/ Mark A. Sirgo, President and CEO

	
	Arius Pharmaceuticals, Inc.
		
	By:	 	 /s/ Mark A. Sirgo, President and CEO

	
	Arius Two, Inc.
		
	By:	 	 /s/ Mark A. Sirgo, President and CEOAllonge by and among the Company to CDC

 Exhibit 10.31 
 ALLONGE 
 This Allonge (this “Allonge”), is dated as of September 5, 2007
(“Effective Date”), between BioDelivery Sciences International Inc. (the “Company”) and CDC IV, LLC (“Payee”, and together with the Company, the “Parties”). 
 WHEREAS, on March 12, 2007, the Company issued a Promissory Note to Payee (the “Note”) in the original principal amount of One
Million Nine Hundred Thousand Dollars ($1,900,000); 
 WHEREAS, in connection with the Parties execution of that certain Royalty Acquisition
and Amendment Agreement (the “Royalty Agreement”) the Company and Payee wish to amend the Note to reflect certain cross defaults provisions. 
 NOW THEREFORE, in consideration of the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree
as follows: 
 1. Capitalized terms used herein and not otherwise defined shall have the meanings given to them in the Note. 
 2. The Company and Payee hereby agree that any breach or default under Section 5(a) of the Royalty Agreement shall be considered an Event of Default
under the Note and, in accordance with Section 6(b) of the Note, result in the immediate acceleration of all obligations thereunder. 
 3. This Allonge constitutes a modification of, and not a novation or discharge of the Note, and except as specifically modified herein, the terms and conditions of the Note shall remain in full force and effect. 
 4. The Company hereby represents and warrants that it has all necessary power and authority, corporate or otherwise, to modify the Note as set forth
above. 
 5. Payee hereby represents and warrants that it has all the necessary power and authority to modify the Note as set forth above.

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS WHEREOF, the parties hereto have executed this Allonge as of the date first above written.

  

			
	COMPANY:
	
	BIODELIVERY SCIENCES INTERNATIONAL INC.
		
	By:	 	 /s/ Mark A. Sirgo

	Name:	 	Mark A. Sirgo
	Title:	 	President and CEO
	
	PAYEE:
	
	CDC IV, LLC
		
	By:	 	 /s/ David Ramsey

	Name:	 	David Ramsey
	Title:	 	PartnerAGREEMENT

      THIS AGREEMENT ("Agreement") is entered into and is effective as of
September 6, 2007, by and between Universal Travel Group, a Nevada corporation
("UTVG") and Richard P. Randall, an individual resident in the State of
Connecticut ("Randall").

                              Preliminary Statement

      UTVG desires to retain Mr. Randall, and Mr. Randall is willing to serve,
as a member of the Board of Directors of UTVG on the terms and subject to the
conditions set forth in this agreement.

      NOW, THEREFORE, in consideration of the mutual promises and agreements set
forth below, UTVG and Mr. Randall hereby agree as follows:

1. Appointment. The Board of Directors of UTVG has elected Mr. Randall, and Mr.
Randall has agreed to serve, as a member of the Board of Directors of UTVG,
effective as of the date of this agreement.

2. Compensation. For the duties and services to be performed by him under this
agreement, UTVG will pay to Mr. Randall, and Mr. Randall agrees to accept, the
compensation described below in this Section 2.

      a. Directors' Fees. UTVG will pay Mr. Randall a director's fee of $20,000
per annum, payable in equal monthly installments commencing September 2007. This
fee represents a retainer for services rendered as a member of its Board of
Directors, and is in addition to any fees to which Mr. Randall may be entitled
under guidelines and rules established by UTVG from time to time for
compensating non-employee directors for serving on, and attending meetings of,
committees of its Board of Directors and the boards of directors of its
subsidiaries.

      b. Equity Component. In addition to the cash fee(s) described in
subsection (a), on the date of this agreement, UTVG will grant Mr. Randall
options to purchase a total of 100,000 shares of UTVG common stock. The exercise
price of these options will be the closing sale price of a share of UTVG common
stock on the OTC Bulletin Board on the date of this agreement. Options to
purchase 33,333 shares may be exercised immediately; options to purchase an
additional 33,333 shares may be exercised commencing July 1, 2008, and options
to purchase the remaining 33,334 shares may be exercised commencing July 1,
2009, provided that in the case of the options to vest in 2008 and 2009 Mr.
Randall is still a director of or otherwise engaged by UTVG. The options will be
granted under UTVG's stock option plan, and will be subject to the terms and
conditions of that plan. Subject to the foregoing vesting provisions and the
terms and conditions set forth in the plan, the options may be exercised until
June 1, 2017, except as otherwise provided in the plan.

<PAGE>

      c. Audit Committee. The Board of Directors has appointed Mr. Randall, and
Mr. Randall has agreed to serve as, Chairman of the Audit Committee and for so
long as he serves in such position he will receive additional compensation of
$7,500 per annum, payable monthly.

3. Expenses. UTVG will reimburse Mr. Randall for reasonable expenses incurred by
him in furtherance of his performance of duties hereunder, provided that such
expenses are substantiated in accordance with UTVG policies applicable to
members of its Board of Directors.

4. Fringe and Medical Benefits. Mr. Randall may participate in any of UTVG's
medical, dental and other benefit programs as are available to non-employee
members of its Board.

5. Term and Termination.

      a. General. The term of this Agreement will commence as of the date the
Board of Directors appoints Mr. Randall a director of UTVG and will remain in
effect as long as Mr. Randall continues to serve as a non-employee director of
UTVG. UTVG has no obligation to cause the nomination or recommend the election
of Mr. Randall to the Board for any period of time in the future. Upon the
termination of Mr. Randall's tenure as a member of the Board, UTVG will promptly
pay to Mr. Randall, or to his estate if his service is terminated upon his
death, all fees accrued for services rendered as a member of the Board and
committees thereof and expense reimbursements due as of the date of termination.

      b. Continuation of Health Benefits. To the extent that health insurance
benefits are provided to Mr. Randall under Section 4 of this Agreement at the
time Mr. Randall's tenure as a member of the Board terminates, other than as a
result of his voluntary resignation, for a period of six-months immediately
after termination, UTVG will maintain in effect, and pay the cost associated
with, health insurance for Mr. Randall with the same coverage provided him prior
to termination (e.g. medical, dental, optical, mental health) and in all other
respects significantly comparable to those in place immediately prior to
termination

6. Indemnification. UTVG shall indemnify Mr. Randall, as a director of UTVG, to
the maximum extent permitted under applicable law against all liabilities and
expenses, including amounts paid in satisfaction of judgments, in compromise, or
as fines and penalties, and counsel fees, reasonably incurred by Mr. Randall in
connection with the defense or disposition of any civil, criminal,
administrative or investigative action, suit or other proceeding, whether civil
or criminal, in which he may be involved or with which he may be threatened,
while an officer or director of UTVG. Expenses (including attorney's fees)
incurred by Mr. Randall in defending any such action, suit or other proceeding
shall be paid by UTVG in advance of the final disposition of such action, suit
or proceeding upon receipt of an undertaking by or on behalf of him to repay
such amount if it shall be ultimately determined that he is not entitled to be

                                       2
<PAGE>

indemnified by UTVG. The right of indemnification provided herein shall not be
exclusive of or affect any other rights to which Mr. Randall may be entitled.
The provisions hereof shall survive expiration or termination of this Agreement
for any reason whatsoever. In the event of any conflict between the provisions
hereof and the indemnification provisions contained in UTVG's articles of
incorporation or bylaws, or in any agreement between UTVG and Mr. Randall, the
terms of such articles, bylaws or agreement shall govern.

      7. Liability Insurance. In furtherance of its agreement to indemnify Mr.
Randall as provided in section 6 hereof, UTVG will maintain in effect at all
times while Mr. Randall continues to serve as a member of the Board liability
insurance provided by a recognized carrier covering members of its Board with a
face amount of no les than $3,000,000 and deductibles of no more than $150,000.
The initial policy acquired in fulfillment of this section has been issued by
Liberty International Underwriters.

      8. Non-Exclusive. Nothing in this agreement will prevent Mr. Randall (1)
from serving as an employee, officer or director of any other company, provided
that such performance is consistent with Mr. Randall's duty of loyalty to UTVG,
(2) from serving on voluntary, community service committees and boards, and (3)
from owning shares representing less than 5% of the outstanding equity
securities of a company that is a competitor of UTVG. Mr. Randall will comply
with and be bound by UTVG's policies, procedures and practices applicable to
members of its Board of Directors from time to time in effect during the term of
this agreement.

      9. Conflicts. Mr. Randall represents that his performance of this
agreement will not conflict with or breach any other agreement to which he is a
party or may be bound. Mr. Randall has not, and will not during the term of this
agreement, enter into any oral or written agreement in conflict with any of the
provisions of this agreement. Mr. Randall represents and warrants that he is not
bound by any agreements which prohibit or restrict him from: (a) competing with,
or in any way participating in a business that competes with, any former
employer or business of any former employer to the extent that Mr. Randall's
performance of his duties under this agreement would be deemed to constitute
such competition; (b) soliciting personnel of a former employer or business to
leave such former employer's employment or to leave such business; or (c)
soliciting customers, suppliers, financing sources or other entities having a
substantial relationship with a former employer or business.

      10. Representations and Warranties of UTVG. UTVG has filed all reports
required to be filed by it under the Securities Act and the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), including pursuant to Section
13(a) or 15(d) thereof, since January 1, 2007 (the foregoing materials being
collectively referred to herein as the "SEC Reports") on a timely basis or has
received a valid extension of such time of filing and has filed any such SEC
Reports prior to the expiration of any such extension. As of their respective
dates, the SEC Reports complied in all material respects with the requirements
of the Securities Act and the Exchange Act and the rules and regulations of the
Securities and Exchange Commission (the "Commission") promulgated thereunder,
and none of the SEC Reports, when filed, contained any untrue statement of a

                                       3
<PAGE>

material fact or omitted to state a material fact required to be stated therein
or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading. The financial
statements of UTVG included in the SEC Reports comply in all material respects
with applicable accounting requirements and the rules and regulations of the
Commission with respect thereto as in effect at the time of filing. Such
financial statements have been prepared in accordance with generally accepted
accounting principles applied on a consistent basis during the periods involved
("GAAP"), except as may be otherwise specified in such financial statements or
the notes thereto, and fairly present in all material respects the financial
position of UTVG and its consolidated subsidiaries as of and for the dates
thereof and the results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal, year-end audit
adjustments.

      There is no claim, action, suit, proceeding, arbitration, reparation,
investigation or hearing, pending or threatened, before any court or
governmental, administrative or other competent authority or private arbitration
tribunal, which could have an adverse effect on the business of UTVG; nor are
there any facts known to UTVG which could reasonably be expected to give rise to
a claim, action, suit, proceeding, arbitration, investigation or hearing, which
could have an adverse effect upon the business of UTVG.

      11. Governing Law; Mediation & Arbitration. This agreement will be
governed by, and construed in accordance with the laws of the State of New York,
without regard to choice-of-law principles, as if made and to be performed
solely in New York.

      12. Notices. All notices or other communications which are required or
permitted hereunder will be in writing and sufficient if delivered personally or
sent by air courier or first class certified or registered mail, return receipt
requested and postage prepaid, addressed as follows:

      If to Mr. Randall, to:        131 Peaceable Street Redding,
                                    Connecticut 06896

      With a copy to:               Goetz Fitzpatrick Most & Bruckman
                                    One Penn Plaza, Suite 4401
                                    New York, New York 10119
                                    Attn: Jack Most, Esq.

      If to UTVG, to:               10940 Wilshire Blvd. Suite 1600
                                    Los Angeles, CA 90024
                                    Attention: President

      with a copy to:               Eaton & Van Winkle
                                    3 Park Avenue
                                    New York, New York 10016
                                    Attn: Vincent J. McGill, Esq.

                                       4
<PAGE>

or to such other address as the party to whom notice is to be given may have
furnished to the other party in writing in accordance herewith. All notices and
other communications given to any party hereto in accordance with the provisions
of this agreement shall be deemed to have been given on the date of delivery if
personally delivered; on the business day after the date when sent if sent by
air courier; and on the third business day after the date when sent if sent by
mail, in each case addressed to such party as provided in this Section or in
accordance with the latest written direction from such party.

      13. Entire Agreement. This agreement constitutes the sole agreement of the
parties and supersedes all oral negotiations and prior writings, including any
and all prior agreements between Mr. Randall and UTVG, with respect to the
subject matter hereof.

      14. Advice of Counsel. EACH PARTY TO THIS AGREEMENT ACKNOWLEDGES THAT, IN
EXECUTING THIS AGREEMENT, SUCH PARTY HAS HAD THE OPPORTUNITY TO SEEK THE ADVICE
OF INDEPENDENT LEGAL COUNSEL, AND HAS READ AND UNDERSTOOD ALL OF THE TERMS AND
PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY
PARTY BY REASON OF THE DRAFTING OR PREPARATION HEREOF.

      15. Counterparts. This agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which shall
constitute one and the same instrument.

      16. Amendments. No modification, waiver, amendment, discharge or change of
this agreement shall be valid unless the same is in writing and signed by the
party against which the enforcement of said modification, waiver, amendment,
discharge or change is sought.

      17. Severability. If any portion of any provision of this agreement, or
the application of such provision or any portion thereof to any person or
circumstance shall be held invalid or unenforceable, the remaining portions of
such provision or portion of such provisions of this agreement or the
application of such provision or portion of such provision as is held invalid or
unenforceable to persons or circumstances other than those to which it is held
invalid or unenforceable, shall not be effected thereby.

                 [signature page appears on the following page]

                                       5
<PAGE>

   [signature page to Agreement of September 6, 2007 between UTVG and Richard
                                    Randall]

      The parties, by signing below, agree to the terms and conditions set forth
in this agreement.

                                 UNIVERSAL TRAVEL GROUP

                                 By: /s/ Jiangping Jiang
                                     -------------------------------------------
                                     Name: Jiangping Jiang
                                     Title: Chairman and Chief Executive Officer

                                     /s/ Richard P. Randall
                                     -------------------------------------------
                                     Richard P. Randall

                                       6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]